Literature DB >> 12406328

Interleukin-10-treated dendritic cells modulate immune responses of naive and sensitized T cells in vivo.

Gabriele Müller1, Anke Müller, Thomas Tüting, Kerstin Steinbrink, Joachim Saloga, Claudia Szalma, Jürgen Knop, Alexander H Enk.   

Abstract

Interleukin-10 is a pleiotropic cytokine known to have inhibitory effects on the accessory functions of dendritic cells. In vitro, interleukin-10 converts immature dendritic cells into tolerizing antigen- presenting cells. To assess whether interleukin-10-treated dendritic cells exert tolerizing effects in vivo, CD4+ T cells from DO11.10 ovalbumin-T cell receptor transgenic mice were transferred to syngeneic BALB/c recipients. Recipient animals were treated with ovalbumin-pulsed/unpulsed, interleukin-10-treated/untreated CD11c+ dendritic cells thereafter and ovalbumin-specific proliferation of lymph node cells was assessed by restimulation with the peptide in vitro. In prophylactic experiments, recipients received naive CD4+ DO11.10 T cells and were immunized with ovalbumin323-339 peptide in incomplete Freund's adjuvant after treatment with various subtypes of dendritic cells. Strong ovalbumin-specific proliferation was observed in animals immunized with control ovalbumin-dendritic cells. Minimal proliferation was found in mice treated with ovalbumin-pulsed, interleukin-10-treated dendritic cells. In therapeutic experiments, preactivated CD4+ DO11.10 T cells were transferred, and recipients were treated with dendritic cells as described. Ovalbumin-specific proliferation was strong in recipients treated with ovalbumin-dendritic cells. CD4+ T cell proliferation from ovalbumin-interleukin-10-dendritic cell treated animals was below background. When delayed type hypersensitivity reactions in the footpads of prophylactically or therapeutically vaccinated animals were tested, mice treated with ovalbumin-interleukin-10-dendritic cells showed no footpad swelling compared with controls. Rechallenge with the antigen in vitro and in vivo did not alter the inhibitory effect of interleukin-10-treated dendritic cells. Thus, interleukin-10-treated dendritic cells inhibit ovalbumin-specific immune responses in naive and sensitized mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406328     DOI: 10.1046/j.1523-1747.2002.00496.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  19 in total

1.  Adoptive transfer of dendritic cells from allergic mice induces specific immunoglobulin E antibody in naïve recipients in absence of antigen challenge without altering the T helper 1/T helper 2 balance.

Authors:  Stephen J Chambers; Eugenio Bertelli; Mark S Winterbone; Mari Regoli; Angela L Man; Claudio Nicoletti
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

Review 2.  Dendritic cells as gatekeepers of tolerance.

Authors:  Ari Waisman; Dominika Lukas; Björn E Clausen; Nir Yogev
Journal:  Semin Immunopathol       Date:  2016-07-25       Impact factor: 9.623

3.  Dual functions of prostaglandin D2 in murine contact hypersensitivity via DP and CRTH2.

Authors:  Yoshihiro Yamamoto; Shinobu Otani; Hiroyuki Hirai; Kinya Nagata; Kosuke Aritake; Yoshihiro Urade; Shuh Narumiya; Hiroo Yokozeki; Masataka Nakamura; Takahiro Satoh
Journal:  Am J Pathol       Date:  2011-05-10       Impact factor: 4.307

4.  Lewis X oligosaccharides targeting to DC-SIGN enhanced antigen-specific immune response.

Authors:  Jingxue Wang; Yongmin Zhang; Jing Wei; Xiaoping Zhang; Bei Zhang; Zhenyuan Zhu; Wei Zou; Yiqin Wang; Zhirong Mou; Bin Ni; Yuzhang Wu
Journal:  Immunology       Date:  2007-03-20       Impact factor: 7.397

5.  Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection.

Authors:  Kobporn Boonnak; Kaitlyn M Dambach; Gina C Donofrio; Boonrat Tassaneetrithep; Mary A Marovich
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

6.  Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells.

Authors:  Shikhar Mehrotra; Arvind Chhabra; Abolokita Chakraborty; Subhasis Chattopadhyay; Mark Slowik; Robert Stevens; Ryan Zengou; Clinton Mathias; Lisa H Butterfield; David I Dorsky; James S Economou; Bijay Mukherji; Nitya G Chakraborty
Journal:  Immunology       Date:  2004-12       Impact factor: 7.397

7.  Differential effect of IL-27 on developing versus committed Th17 cells.

Authors:  Mohamed El-behi; Bogoljub Ciric; Shuo Yu; Guang-Xian Zhang; Denise C Fitzgerald; Abdolmohamad Rostami
Journal:  J Immunol       Date:  2009-09-28       Impact factor: 5.422

8.  Induction of IL-10 producing CD4+ T cells with regulatory activities by stimulation with IL-10 gene-modified bone marrow derived dendritic cells.

Authors:  C-L Fu; Y-H Chuang; H-Y Huang; B-L Chiang
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

9.  Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases.

Authors:  Peter Terness; Thilo Oelert; Sandra Ehser; Jing Jing Chuang; Imad Lahdou; Christian Kleist; Florian Velten; Günter J Hämmerling; Bernd Arnold; Gerhard Opelz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-18       Impact factor: 11.205

10.  Effect of immune tolerance induced by immature dendritic cells and CTLA4-Ig on systemic lupus erythematosus: An in vivo study.

Authors:  Cuili Huang; Lidan Zhang; Fang Ling; Sijian Wen; Yanyan Luo; Hui Liu; Jingping Liu; Wenjun Zheng; Ming Liang; Jian Sun; You-Kun Lin
Journal:  Exp Ther Med       Date:  2018-01-04       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.